cancer-gi-cancer-digestive-2018-scientifictracks

29 / 30

Page 74
Notes:
Journal of Gastrointestinal & Digestive System | ISSN: 2161-069X | Volume: 8
&
&
October 29-30, 2018 | San Francisco, USA
International Conference on
Gastrointestinal Cancer and Therapeutics
4th World Congress on
Digestive & Metabolic Diseases
26th Annual Congress on
Cancer Science and Targeted Therapies
Breast cancer related antigen: Acceptability and implications in Indian population
Akhil Jain
International Oncology Center, Fortis Hospital, India
Breast cancer is most common cancer in India as stated by the recent release of the International Agency for Research on
Cancer (Globocon 2018). Hereditary causes of breast cancer are well known and Breast Cancer Related Antigen ( BRCA)
gene mutation is the most common of them. Besides breast cancer, BRCA mutation has been shown to an etiologic factor for
other cancers like ovarian, uterine, prostate, pancreatic cancers, multiple cancers in an individual or family members. In India,
BRCA gene mutational analysis is not readily accepted by the patients despite its important implications in family screening
and treatment for the metastatic mutant disease. We did a retrospective analysis of 53 breast cancer patients who attended
tertiary cancer care hospital in National Capital Region of India between January 2016 and August 2018 and were eligible for
BRCA gene mutation testing. All patients were properly given pre-genetic counseling. Out of 53 patients, only 22(41.5%) finally
consented for analysis of germline BRCA gene mutation. Twenty patients were enrolled in government insurance schemes and
only 2 were self-employed. Thirteen (59%) patients had breast cancer, 3(13.6%) had both breast and ovarian cancer, 4 (18%)
had ovarian cancer, one (4%) had uterine cancer and one (the only male patient) had prostate cancer. Of these 22 analyzed
patients, 4(18%) were found to be having germline BRCA mutation. BRCA-1 was mutated in one patient and BRCA-2 in three
patients. One patient and her family denied for post-genetic counseling and did not attend the outpatient clinic further. Rest
three families attended educational and awareness programs and consented for screening all in terms of germline mutational
investigation, regular clinical and radiological follow-up. Since one of these patients was having recurrent and metastatic breast
cancer, she was started on Olaparib and showed a clinical response. Thirty-one patients (58.5%) refused the investigation due
to financial constraints, social stigma and unwillingness to adopt prophylactic measures in case germline mutation turned out
to be positive. Due to various social, economic and psychological barriers, the acceptability of BRCA analysis is poor in the
Indian scenario. Denial for germline analysis in indicated clinical situations may delay or miss out the diagnosis of hereditary
cancer syndromes and jeopardize the needed screening of family members for the possible malignancies.
Biography
Akhil Jain, Senior Medical Oncologist, has been practicing medicine at Fortis (IOSPL) Hospital, Noida. Having begun his career at BJ Medical College, Ahmedabad,
Gujarat, India, he has worked at various reputed hospitals such as Sanjay Gandhi Memorial Hospital, Delhi; Ram Manohar Lohia Hospital, Delhi; The Gujarat
Cancer and Research Institute; BJ Medical College, Ahmedabad; Action Cancer Hospital, Paschim Vihar; prior to his current position. He is a proud alumnus of
BJ Medical College, Ahmedabad, Gujarat where he graduated with an MD in Internal Medicine. He conducted his postdoctoral work at The Gujarat Cancer and
Research Institute BJ Medical College, Ahmedabad, Gujarat, procuring a DM Superspecialty degree in Medical Oncology. He holds professional memberships
at reputed cancer organizations such as ESMO (European society for medical oncology), and other prestigious associations. He has contributed to number of
national and international publications and has been part of various clinical trials and scientific projects. He has been awarded with “Utkrisht Sewa Samman” for his
contributions towards “No Tobacco Campaign”.
Akhil Jain, J Gastrointest Dig Syst 2018, Volume 8
DOI: 10.4172/2161-069X-C8-085